Article
Genotype-Guided Antidepressant Prescribing for Patients With Depression: A Randomized Clinical Trial.
JAMA network open - 1 May 2026
Blake Kathryn V, Hines Lindsay J, Liu Michelle, Myers Rachel A, Baye Jordan F, Cavanaugh Kerri L, Duong Benjamin Q, Hulvershorn Leslie A, Mathews Carol A, Murrough James W, Orlando Lori A, Petry Natasha J, Tillman Emma M, Sadeghpour Azita, Voora Deepak, Block Sara L, Cicali Emily J, Clermont Sabrina, Elwood Erica N, Harris Elizabeth C, Nguyen Khoa A, Ramos Michelle A, Rosenman Marc B, Shroff Nandini, Shuman Saskia, Wyatt Christina, Horowitz Carol R, Volpi Simona, Singh Rajbir, Rider Renee A, Chakraborty Hrishikesh, Dexter Paul R, Johnson Julie A, Skaar Todd C, Cavallari Larisa H, Peterson Josh F
Abstract excerpt
Importance: The effectiveness of pharmacogenetics to guide prescribing of selective serotonin reuptake inhibitors (SSRIs) for depression remains unclear, despite the well-established association between SSRI pharmacokinetics and genetic variation. Objective: To determine whether pharmacogenetic-guided prescribing of SSRIs improves treatment response in patients with depression. Design, Setting, and Participants:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.